Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii

References

• Martin CA. Invasive fungal infections in the critically ill patient. J Pharm Prac 2005; 18:9–17.
   Google Scholar
• Eisenman HC, Casadevall A, McClelland EE. New insights on the pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Reports 2007; 9:457–464.
   PubMedGoogle Scholar
• Chaayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 2006; 20:507–544.
   PubMedGoogle Scholar
• Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48:693–715.
   PubMed Web of Science ®Google Scholar
• Bicanic T, Harrison TS. Cryptococcal meningitis. British Med Bulletin 2004; 72:99–118.
   PubMed Web of Science ®Google Scholar
• Aller AI, Martin-Mazuelos E, Lozano F, . Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44:1544–1548.
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Clinical efficacy of new antifungal agents. Curr Opin Microbiol 2006; 9:483–488.
   PubMed Web of Science ®Google Scholar
• Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanism of action. Trends in Microbiol 2003; 11:272–279.
   PubMed Web of Science ®Google Scholar
• Xu J, Onyewu C, Yoell HJ, . Dynamic and heterogenous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob Agents Chemother 2001; 45:420–427.
   PubMedGoogle Scholar
• Onyewu C, Blankenship JR, Del Poeta M, Heitman J. Ergosterol bio-synthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata and Candida krusei. Antimicrob Agents Chemother 2003; 47:956–964.
   PubMed Web of Science ®Google Scholar
• Marchetti O, Entenza JM, Sanglard D, . Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 2000; 44:2932–2938.
   PubMed Web of Science ®Google Scholar
• Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006; 8:415–416.
   Google Scholar
• Fischer MJE, Paulussen JJC, Horbach DA, . Inhibition of mediator release in RBL-2H3 cells by some H1-antagonist derived anti-allergic drugs: relation to lipophilicity and membrane effects. Inflamm Res 1995; 44:92–97.
   PubMedGoogle Scholar
• Chamilos GMS, Lionakis ER, Lewis E, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infect Dis 2007; 7:42–55.
   PubMed Web of Science ®Google Scholar
• Myloakis ER, Moreno JB, Khoury EL, . Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 2005; 73:3842–3850.
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Reference method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition, M27-A2, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898 USA, 2004.
   Google Scholar
• Taglialatela M, Timmerman H, Annunziato L. Cardiotoxic potential and CNS effects of first-generation antihistamines. Trends Pharmacol Sci 2000; 21:52–56.
   PubMed Web of Science ®Google Scholar
• Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus ooctyes by the histamine receptor antagonist terfenadine and astemizole. FEBS Lett 1996; 385:77–80.
   PubMed Web of Science ®Google Scholar
• Wulff H, Miller MJ, Hansel W, . Design of a potent selective inhibitor of the intermediate-conductance Ca2 + -activated K+ channel, IKCa1: a potential immunosuppressant. PNAS 97:8151–8156.
   Google Scholar
• Hong Nguyen M, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995; 39:1691–1695.
   PubMedGoogle Scholar
• Barchiesi F, Gallo D, Caselli F, . In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999; 44:65–70.
   PubMedGoogle Scholar
• Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991; 35:726–729.
   PubMed Web of Science ®Google Scholar
• Nucci M, Perfect JR. When primary antifungal therapy fails. Clin Infect Dis 2008; 46:1426–1433.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M. Combinations of antifungal agents in therapy – what value are they? J Antimicrob Chemother 2004; 54:854–869.
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Denning D. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61(Suppl. 1): i19–130.
   PubMedGoogle Scholar